Kedudukan dalam Saham
#38936
Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a... Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a molecular diagnostics company dedicated to the early detection of cancer through liquid biopsy methods. Its primary offering, Epi proColon, is a blood-based assay specifically developed for the early identification of colorectal cancer, distributed across the United States, Europe, and China. The company's portfolio further encompasses a blood test for hepatocellular carcinoma and Epi BiSKit, a pre-analytical solution providing reagents essential for preparing bisulfite-converted DNA. Epigenomics' research and development initiatives are focused on pinpointing relevant biomarkers in human tissue and subsequently creating and securing patents for associated in vitro diagnostic blood tests.
Harga Saham
$0.83030862
Disegerakkan terakhir: 2024-06-27
Perubahan (1 hari)
-1.35%
Perubahan (1 tahun)
0.00%
Perdagangan Epigenomics AG (ECX)
Harga ECX dengan permodalan pasaran b
Modal pasaran bagi Epigenomics AG(ECX)
Modal Pasaran: $726.64K
Sehingga August 2026, Epigenomics AG mempunyai modal pasaran sebanyak $726.64K. Ini menjadikan Epigenomics AG syarikat ke-38936th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Epigenomics AG dari 2014 hingga 2026
ECX berbanding dengan 5 teratas yang paling popular stocks
| Harga ECX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.470T
|
+752,711,453.14%
|
|
|
|
|
$4.467T
|
+614,753,146.04%
|
|
|
|
|
$4.174T
|
+574,424,088.62%
|
|
|
|
|
$3.700T
|
+509,200,320.84%
|
|
|
|
|
$2.854T
|
+392,811,288.04%
|
